Meeting
2018 Gastrointestinal Cancers Symposium
Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).
Authors
Ian Chau
Royal Marsden NHS Foundation Trust, London, United Kingdom
Ian Chau , Nicolas Penel , Hendrik-Tobias Arkenau , Rafael Santana-Davila , Emiliano Calvo , Andres O. Soriano , Gu Mi , Jin Jin , David Ferry , Roy S. Herbst , Charles S. Fuchs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02443324
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 101)
DOI
10.1200/JCO.2018.36.4_suppl.101
Abstract #
101
Poster Bd #
H5
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.
First Author: Roy S. Herbst
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
First Author: Sun Young Rha
Poster
2020 Gastrointestinal Cancers Symposium
An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706).
First Author: Akihito Kawazoe
Poster
2018 ASCO Annual Meeting
Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.
First Author: Roy S. Herbst